RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma
S. Lambing, S. Holdenrieder, P. Müller, Y. P. Tan, C. Hagen, S. Garbe, M. Schlee, J. G. van den Boorn, E. Bartok, G. Hartmann, M. Renn
This study shows that RIG-I ligands enhance radiation-induced tumor cell death and immunogenicity in melanoma, with p53 playing a key role in the synergy between RIG-I and radiation.
bioRxiv · Oct 16, 2021Immunology